Lexaria Bioscience Corp.

86 articles about Lexaria Bioscience Corp.

• Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

  3/11/2021

  Lexaria today announced that CEO Chris Bunka is presenting and will be available to meet with investors and analysts on a one-on-one basis at the 33rd Annual Virtual ROTH Conference to be held on March 15-17, 2021.

• Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection

  2/16/2021

  Lexaria Bioscience's drug delivery technology, DehydraTECHTM improves the "bioavailability" of pharmaceutical ingredients.

• 

  2021 Biopharma Update on the Novel Coronavirus: February 16

  2/16/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.

• Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies

  2/11/2021

  Lexaria Bioscience Corp. a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus on hypertension.

• Lexaria Provides Guidance on Upcoming R&D

  2/1/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces applied R&D programs to begin immediately.

• Lexaria Appoints New Board Member

  1/15/2021

  Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors.

• Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

  1/15/2021

  Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)) today announced the closing of its previously announced underwritten public offering (the of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$).

• Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering

  1/12/2021

  Lexaria Bioscience Corp. today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols and respectively.

• Lexaria Announces Effective Date for Reverse Stock Split

  1/8/2021

  Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX); or a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021

• Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH

  12/22/2020

  Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the a global innovator in drug delivery platforms, today announced that it has initiated the next phase of its antiviral drug research program following successful results from a recent animal study announced on December 1, 2020.

• Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets

  12/10/2020

  Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the , a global innovator in drug delivery platforms, announces that it has closed the sale of its non-pharmaceutical THC-related assets held within Lexaria Canpharm ULC, a Lexaria wholly-owned subsidiary, to Hill Street Beverage Company Inc.

• Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences

  12/7/2020

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that its Chairman & CEO Chris Bunka is scheduled to present at four upcoming investor conferences in December 2020 and January 2021.

• Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs

  12/1/2020

  Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19

• Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

  11/19/2020

  Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement, through its wholly owned subsidiary Lexaria Canpharm ULC, to sell certain non-core, non-pharmaceutical THC-related business assets for gross proceeds of $3.85 million CDN.

• Lexaria Bioscience Advances 2021 Strategic Initiatives

  11/5/2020

  Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to outline its planned strategic initiatives for 2021 with a sharply enhanced focus on solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.

• Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected

  10/22/2020

  Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to announce that it is exceeding expectations for volume of servings of its patented DehydraTECHTM enabled CBD powders, to be processed during the Company's fiscal Q1 2021 ending November 30, 2020.

• Lexaria Bioscience Granted First European Patent for DehydraTECH Technology

  10/21/2020

  Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.

• Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs

  9/29/2020

  Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications

• Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders

  9/23/2020

  Lexaria Bioscience Corp. is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings of its patented DehydraTECHTM enabled CBD powders,

• 

  Biopharma Update on the Novel Coronavirus: June 19

  6/19/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.